David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577). To see the French language version of this video, please click here.

Leukemia

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Multiple Myeloma

Sagar Lonial, MD, and Torben Plesner, MD

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).

Leukemia

Julie Vose, MD, MBA

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).

Jul

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality

Patients With Prostate Cancer Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Update on LEANer Trial in Patients With Breast Cancer

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors Long-Term Outcomes

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma